Product Images Sacubitril And Valsartan
View Photos of Packaging, Labels & Appearance
- 60 tablets - sacubitrilvalsartan 24 26 mg
- 60 tablets - sacubitrilvalsartan 49 51 mg
- figure 7 - sacubitrilvalsartan 7 figure
- 60 tablets - sacubitrilvalsartan 97 103 mg
- sacubitrilvalsartan-fig-2 - sacubitrilvalsartan fig 2
- Figure 1 - sacubitrilvalsartan fig1
- Figure 3 - sacubitrilvalsartan fig3
- Figure 4 - sacubitrilvalsartan fig4
- figure 6 - sacubitrilvalsartan figur6
- figure 5 - sacubitrilvalsartan figure5
- Structure - sacubitrilvalsartan str
Product Label Images
The following 11 images provide visual information about the product associated with Sacubitril And Valsartan NDC 46708-557 by Alembic Pharmaceuticals Limited, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
60 tablets - sacubitrilvalsartan 24 26 mg
60 tablets - sacubitrilvalsartan 49 51 mg
figure 7 - sacubitrilvalsartan 7 figure
60 tablets - sacubitrilvalsartan 97 103 mg
This text provides information about Sacubitril and Valsartan tablets, each containing 97mg of Sacubitril and 103mg of Valsartan. The usual dosage instructions are not provided, so it is recommended to refer to prescribing information. The tablets should be stored at a temperature between 15-30°C, protected from moisture, and kept out of reach of children. The text mentions the manufacturer, Alembic Pharmaceuticals Ltd, and includes their contact details. This medication requires a prescription and the packaging contains 60 tablets. The NDC (National Drug Code) number for these tablets is 46708-558-60.*
sacubitrilvalsartan-fig-2 - sacubitrilvalsartan fig 2
Figure 1 - sacubitrilvalsartan fig1
This text provides information on the coadministered drugs, including Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HETZ, Metformin, Atorvastatin, and Sildenafil. It mentions the geometric mean ratio and 90% confidence intervals for these drugs. The document also indicates a change relative to a reference.*
Figure 3 - sacubitrilvalsartan fig3
This data presents the time to first occurrence of cardiovascular (CV) death or heart failure hospitalizations in a study called PARADIGM-HF. The analysis shows the comparison between two treatments: sacubitril and valsartan versus enalapril. The results indicate a significant difference in favor of sacubitril and valsartan as compared to enalapril, with a p-value of less than 0.0001. The number of individuals at risk over time is also provided for each treatment group.*
Figure 4 - sacubitrilvalsartan fig4
This data table provides information on the distribution of various factors in a population, such as age, gender, weight, race, medical conditions, medication use, and outcomes related to heart failure treatments (Sacubitril and Valsartan vs. Enalapril). The table shows the percentage of individuals falling into different subgroups based on these factors and also includes the hazard ratios for the two treatments, with Sacubitril and Valsartan being considered better in this comparison.*
figure 6 - sacubitrilvalsartan figur6
figure 5 - sacubitrilvalsartan figure5
Structure - sacubitrilvalsartan str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
